{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:45:20Z","timestamp":1761093920668,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.anai.2022.02.006","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T02:17:28Z","timestamp":1645755448000},"page":"602-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in pharmacologic treatment of chronic idiopathic urticaria from 2016 to 2020"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-8468","authenticated-orcid":false,"given":"Lily","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan E.","family":"Landon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.anai.2022.02.006_bib0001","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2022.02.006_bib0002","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2022.02.006_bib0003","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/jdv.14075","article-title":"Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic\/spontaneous urticaria: analyses according to the presence or absence of angioedema","volume":"31","author":"Maurer","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.anai.2022.02.006_bib0004","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2022.02.006_bib0005","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","article-title":"The diagnosis and management of acute and chronic urticaria: 2014 update","volume":"133","author":"Bernstein","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2022.02.006_bib0006","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2500\/aap.2018.39.4132","article-title":"Real-world use of omalizumab in patients with chronic idiopathic\/spontaneous urticaria in the United States","volume":"39","author":"Eghrari-Sabet","year":"2018","journal-title":"Allergy Asthma Proc"},{"issue":"7","key":"10.1016\/j.anai.2022.02.006_bib0007","first-page":"598","article-title":"Real-world characteristics and treatment patterns in patients with urticaria initiating omalizumab in the United States","volume":"24","author":"Ke","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"10.1016\/j.anai.2022.02.006_bib0008","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.anai.2022.02.006_bib0009","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jaip.2017.07.034","article-title":"Trends in omalizumab utilization for asthma: evidence of suboptimal patient selection","volume":"6","author":"Jeffery","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2022.02.006_bib0010","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622001235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622001235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:29:23Z","timestamp":1761053363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1081120622001235"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2022.02.006","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in pharmacologic treatment of chronic idiopathic urticaria from 2016 to 2020","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2022.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}